Topics

BIND Therapeutics and Synergy Pharmaceuticals Company Profile

22:15 EDT 21st September 2019 | BioPortfolio


News Articles [2073 Associated News Articles listed on BioPortfolio]

Bausch Health to buy certain Synergy Pharmaceuticals assets for $195m

Canada-based Bausch Health Companies has won a bid to acquire certain assets of US-based biopharmaceutical firm Synergy Pharmaceuticals for a...Read More... The post Bausch Health to buy certain Syner...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP

NEW YORK, April 10, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. ("Synergy" or the "Company") (NAS...

Bausch Health to buy certain assets of Synergy Pharmaceuticals

“As we continue to transform Bausch Health, we are now pivoting to offense with research investments and strategic acquisitions that augment our core businesses. We are excited to The post Baus...

Frequency Therapeutics Names Dana Hilt Chief Medical Officer

Frequency Therapeutics has appointed Dana Hilt to serve as its chief medical officer, the same position he held at Lysosomal Therapeutics. His experience also includes positions at FORUM Pharmaceutica...

Gemini Therapeutics Picks Orchard’s Jason Meyenburg for CEO

Jason Meyenburg has been appointed CEO of Gemini Therapeutics. He is also joining the Cambridge, MA, company’s board of directors. Meyenburg was most recently chief commercial officer of Orchard The...

Johnson & Johnson Vision launches TECNIS Synergy IOL in Europe

Johnson & Johnson Vision has introduced TECNIS Synergy continuous-range-of-vision intraocular lens (IOL) to treat cataract patients in the Europe, Australia and New Zealand. TECNIS Synergy, which ...

Neoleukin Therapeutics, Aquinox Pharmaceuticals complete merger transaction

Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” beginning on Monday, August 12, 2019, on the Nasdaq Global The post Ne...

$BHC $SGYP Bausch Health Co. Inc. Acquires Certain Assets of Synergy Pharmaceuticals Inc. for Approx. $195M in Cash

$BHC $SGYP Bausch Health Co. Inc. Acquires Certain Assets of Synergy Pharmaceuticals Inc. for Approx. $195M in Cash

PubMed Articles [833 Associated PubMed Articles listed on BioPortfolio]

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Occurrence and distribution of pharmaceuticals in raw, finished, and drinking water from seven large river basins in China.

The occurrence of pharmaceuticals in the drinking water is a growing concern in China. In this study, we determined the concentration and distribution of 59 selected pharmaceuticals in raw, finished, ...

U.S. Emergency Department Visits Resulting From Nonmedical Use of Pharmaceuticals, 2016.

National data on morbidity from nonmedical use of pharmaceuticals are limited. This study used nationally representative, public health surveillance data to characterize U.S. emergency department visi...

Simultaneous aqueous chlorination of amine-containing pharmaceuticals.

Amine-containing pharmaceuticals such as acetaminophen, diclofenac, and sulfamethoxazole are the most often detected pharmaceuticals in wastewater and other aquatic environments. Amine-containing phar...

Clinical Trials [659 Associated Clinical Trials listed on BioPortfolio]

A 2x2 Factorial Randomized Controlled Trial of Colchicine and Spironolactone in Patients With STEMI Who Have Undergone PCI With SYNERGY Stent Registry

The CLEAR SYNERGY trial will study the long term effects of three multidisciplinary treatments following PCI to treat ST elevation myocardial infarction. These treatments address both the ...

IRIS-Synergy Cohort in the IRIS-DES Registry

The purpose of this study is to evaluate the relative effectiveness and safety of Synergy stent compared to other drug eluting stents.

Safety and Performance Evaluation of CircuLite Synergy

The purpose of the study is to demonstrate the safety and functionality of the CircuLite Synergy Pocket Circulatory Assist Device.

Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy

To compare the incidence of major adverse cardiac events among a series of patients receiving the Synergy drug-eluting stent with bioabsorbable polymer to historical controls who have rece...

A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

EVOLVE 4.5/5.0 is a prospective, single-arm, multi-center observational (standard of care) trial intended to confirm the safety and effectiveness of the SYNERGY 4.50 mm and 5.00 mm Coronar...

Companies [2765 Associated Companies listed on BioPortfolio]

BIND Therapeutics and Synergy Pharmaceuticals

BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Me...

BIND Therapeutics, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering pl...

Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug SP-304 is a synthetic a...

BIND Therapeutics and Navidea Biopharmaceuticals

BIND Therapeutics is a clinical-stage nanomedicine platform company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration...

More Information about "BIND Therapeutics and Synergy Pharmaceuticals" on BioPortfolio

We have published hundreds of BIND Therapeutics and Synergy Pharmaceuticals news stories on BioPortfolio along with dozens of BIND Therapeutics and Synergy Pharmaceuticals Clinical Trials and PubMed Articles about BIND Therapeutics and Synergy Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BIND Therapeutics and Synergy Pharmaceuticals Companies in our database. You can also find out about relevant BIND Therapeutics and Synergy Pharmaceuticals Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record